For two of the biggest obstacles to curbing the pandemic, it won't just be federal officials who will lead the way, says Dr. Celine Gounder, a member of President Biden's COVID-19 advisory board.
Clinicians in private practice, those who work for staffing agencies and others who are not directly employed by hospitals or long-term care facilities say they have been overlooked in the rollout.
Dr. Chizoba Barbara Wonodi of Johns Hopkins University explains why a strategy to vaccinate everyone may not be the best approach to fighting the virus in lower-income countries such as Nigeria.
"I feel like healing is coming," New York critical care nurse Sandra Lindsay said after receiving her shot. "I hope this marks the beginning to the end of a very painful time in our history."
The U.K. was the first Western country to approve Pfizer's coronavirus vaccine for emergency use. In the U.S., the Food and Drug Administration could vote to approve the vaccine as early as Thursday.
Pew Research Center found 83% of Asian Americans said they would get a vaccine compared to 42% of Blacks. White and Latinx respondents were about even with 63% and 61% respectively saying they would.
The new ban is an expansion of the social network's rules against misinformation that could lead to imminent physical harm. It comes as governments prepare to roll out the first vaccinations.
Watch an expert panel discussion on the effort to develop and deploy safe and effective vaccines against COVID-19 on Friday, Nov. 20, to be live-streamed here at 12 p.m. ET
Pfizer's COVID-19 vaccine is the first to have data showing that it exceeded the minimum effectiveness threshold set by the Food and Drug Administration for emergency use.
Most of the federal contracts with companies involved in the crash program to make COVID-19 vaccines haven't been made public. The lack of disclosure raises questions about accountability.
A panel of doctor and scientists raised questions about the expedited regulatory path the Food and Drug Administration is considering for COVID-19 vaccines.
Here's irony: tobacco plants may be key in preventing COVID-19. Two companies are using the plants to produce proteins for a vaccine. One candidate vaccine is already in a clinical trial.
The move is a reversal of Facebook's longstanding reluctance to block problematic content. Critics say public health misinformation has flourished on the social network.
The requirements laid out by the Food and Drug Administration in advice for drugmakers underscore why it's unlikely a vaccine could clear the agency before Election Day.
Volunteers getting the shot help determine if a candidate vaccine works. But what with social distancing and masks, scientists must discern if it's the shot or these other measures preventing illness.
"We've got to take a deep breath," says one health official about the rapid timeline pushed by the CDC. "It is very clear that we need to lean forward to prepare to deliver the vaccine."
New vaccines usually take years to get the approval of the Food and Drug Administration. But the Trump administration suggests the FDA may greenlight a coronavirus vaccine by the end of the year.
The World Health Organization's Tedros Adhanom Ghebreyesus says he fears that without global cooperation ensuring equal access to COVID-19 vaccines, some countries could resort to hoarding.
The presumptive Democratic nominee now leads President Trump by 11 points. And more people are worried about the coronavirus, but 35% still say they won't get vaccinated when one's available.
Moderna, one of the leading horses in the coronavirus vaccine race, has already made deals at between $32 and $37 a dose for some foreign countries. The U.S. price is expected to be lower.
Adjuvants play a crucial role in many vaccines' effectiveness. Some scientists say there needs to be more research into developing a wider variety of adjuvants because of how important they are.
